Trials
5 active
11 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide. The IMP will be administered as half-strength twice daily, based on the body weight of the patient.”In the company’s words, NCT06578507 on ClinicalTrials.gov
- Tested for
- Sickle Cell Disease
- Main trialPhase 2
- “The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months”In the company’s words, NCT06578507 on ClinicalTrials.gov
- Other names
- Hydroxycarbamid · Siklos · hydroxyurea
Other drugs for Sickle Cell Disease
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- CTX001Vertex Pharmaceuticals · Phase 3
- L-citrullineAsklepion Pharmaceuticals, LLC · Phase 3
- RilzabrutinibSanofi · Phase 3
- EtavopivatNovo Nordisk · Phase 3
Coming up1
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Feb 2028 | Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease | |
| Phase 4Completed | Nov 2016 | Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) | |
| Phase 2Completed | 28 Oct 2022 | Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease. | |
| Phase 2Completed | 30 May 2024 | SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial) | |
| Phase 1Completed | 29 Sep 2021 | A Bioequivalence Study to Compare the Pharmacokinetics of Two Formulations of Hydroxycarbamide in Healthy Volunteers | |
| Phase 1/2Authorised | not given | A phase 1/2 multicenter open-label study to investigate treatment of hydroxyurea (HU) in combination with valproic acid (VPA) or 6- mercaptopurine (6-MP) in combination with VPA in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) considered unfit for standard chemotherapy | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 1/2Authorised | not given | HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multi-centre study to assess the tolerability and efficacy of the addition of hydroxyurea to standard ara-C and daunorubicin-based therapy for adults (age ≥ 18 years of age) with newly diagnosed acute myeloid leukaemia (AML) | |
| Phase 2Ended | not given | Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial | |
| Phase 4Ended | not given | Optimization of the management of drepanocytosis patients treated with hydroxyurea: Interest of the pharmacological therapeutic follow-up | |
| Phase 1/2Authorised | not given | FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026